secwatch.observer — SEC 8-K summary
======================================

Issuer:     Syndax Pharmaceuticals Inc (SNDX)
CIK:        0001395937
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001193125-26-010486
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Syndax reports preliminary 2025 Revuforj $125M, Niktimvo $152M net rev, cash $394M
--------------------------------------------------------------------------------

- Revuforj preliminary net revenue $44M (Q4) and $125M (FY), up 38% QoQ.
- Niktimvo preliminary net revenue $56M (Q4) and $152M (FY); Syndax's 50% profit share expected ~25-30% of net rev.
- Cash, equivalents and marketable securities ~$394M at year-end 2025 (unaudited).
- 2026 R&D + SG&A expense guidance ~$400M (excl. $50M non-cash stock comp); company funded to profitability.
- Key 2026 milestones: complete IPF trial enrollment, advance frontline Phase 3 revumenib trials, initiate MF proof-of-principle.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526010486/0001193125-26-010486-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1395937/000119312526010486/sndx-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-010486

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer